Search results - Portal of Medical Data Models (MDM-Portal)

GECCO - German Corona Consensus - Covid-19 Research-Dataset - Medical History/Risk factors (Anamnese/Risikofaktoren)

- 1/13/21 - 13 forms, 1 itemgroup, 88 items, 1 language

Itemgroup: Anamnese/Risikofaktoren

This version of the GECCO logical model is based on https://art-decor.org/art-decor/decor-datasets--covid19f- on the "final" version published mid to end September 2020. For actual use of FHIR profiles, please use the profiles available on https://simplifier.net/ForschungsnetzCovid-19/ResearchDatasetGECCO/~overview (FHIR download on MDM is only a FHIR questionnaire profile). A few items implicated by comments/descriptions of items on art-decor have been added: "Datum der letzten Impfung" (date of last vaccination for all listed vaccinations), "Schweregrad" (Severity of Kidney Diseases), "Ort" (Location of vacation in the last 14 days), "Befund bildgebender Verfahren im Rahmen von COVID-19" added separately for all types of imaging procedures listed, "Symptom Schweregrad" (Severity of Symptoms) for each symptom listed, and an "NCT-/EudraCT-Nummer" item for Study participation. Official German text from http://cocos.team/datasets.html: Zur Bewältigung der aktuellen Pandemie und der damit einhergehenden Behandlung von Patienten fördert das Bundesministerium für Bildung und Forschung (BMBF) ein nationales Netzwerk der Universitätsmedizin im Kampf gegen COVID-19. Unter anderem soll das Netzwerk die Daten der behandelten COVID-19 Patienten systematisch erfassen und bündeln. Die Forschenden sollen die Behandlung der COVID-19-Patienten standardisiert erheben, verfolgen und analysieren. Die hohe Bedrohungslage hat zu intensiver wissenschaftlicher Aktivität zu COVID-19 geführt, wozu zahlreiche regionale, nationale und internationale epidemiologische Erhebungen und Registerstudien zählen. Der Konsensusdatensatz gibt der Wissenschaft um COVID-19 eine gemeinsame Sprache und Arbeitsgrundlage. Inofficial translation: In order to cope with the current pandemic and the associated treatment of patients, the Federal Ministry of Education and Research (BMBF) is funding a national network of university medicine in the fight against COVID-19. Among other things, the network will systematically collect and bundle the data of the treated COVID-19 patients. The researchers are to collect, track and analyze the treatment of COVID-19 patients in a standardized way. The high threat level has led to intensive scientific activity on COVID-19, including numerous regional, national and international epidemiological surveys and register studies. The consensus data set provides a common language and working basis for the science around COVID-19. Not yet integrated: Items for "Data Absent Reason", "Certainty of Presence", "Uncertainty of Presence", and "Certainty of absence"; "therapeutic intention", "Medication Statement Status", "EventStatus"; longer versions of the ValueSets published separately from the variables in art-decor.

Studieneinschluss/Einschlusskriterien

1 itemgroup, 3 items

8 more forms meeting the search are available in the detailed view.

ISARIC/WHO Novel Coronavirus (nCoV) / COVID-19 Case Record Form - MODULE 3: OUTCOME CASE REPORT FORM

- 1/18/21 - 1 form, 12 itemgroups, 138 items, 1 language

Itemgroups: Participant Identification, Treatment, Complications, Diagnostics, Biospecimen Testing, Antiviral therapy, Antibiotic therapy, Corticosteroids, Heparin, Antifungal therapy, Other treatments administered for COVID-19, Outcome

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies. Module 1 and Module 2 complete on the first day of presentation/admission or on first day of COVID-19 assessment. Module 2 also complete on first day of admission to ICU or high dependency unit. In addition, complete daily for as many days as resources allow up to a maximum of 14 days. Continue to follow-up patients who transfer between wards. Module 3 (Outcome) complete at discharge or death General Guidance: - The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date. - For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline - Participant Identification Numbers consist of a 3 digit site code and a 4 digit participant number. You can obtain a site code and registering on the data management system by contacting ISARIC. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page. - Printed paper CRFs may be used for later transfer of the data onto the electronic database. - For participants who return for re-admission to the same site, start a new form with a different Participant Identification Number. Please check “YES-admitted previously” in the ONSET & ADMISSION section. Enter as 2 separate entries in the electronic database. - For participants who transfer between two sites that are both collecting data on this form, it is preferred to have the data entered by a single site as a single admission, under the same Participant Identification Number. When this is not possible, the first site should record “Transfer to other facility” as an OUTCOME, and the second site should start a new form with a new patient number and indicate “YES-transferred” in ONSET & ADMISSION. - Complete every line of every section, except for where the instructions say to skip a section based on certain responses. - Mark ‘Not done’ for any results of laboratory values that are not available, not applicable or unknown. - Avoid recording data outside of the dedicated areas. Sections are available for recording additional information. - If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS. - Place an (X) when you choose the corresponding answer. To make corrections, strike through (-------) the data you wish to delete and write the correct data above it. Please initial and date all corrections. - Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder. - ISARIC would like the centers to enter data directly into their electronic data capture system. Please contact ISARIC about access. If your site would like to collect data independently, ISARIC can support you in the estabilishment of locally hosted databases. This version may serve as a basis for locally hosted databases. - Please contact ISARIC, if you need help with databases, have comments or to let ISARIC know that you are using the CRF. - Please let us know if you find any mistakes in the MDM Portal's version. FURTHER GUIDANCE AND DEFINITIONS (from the Completion guideline) Comorbidities: Comorbidities present before the onset of COVID-19 and are still present. Do not include those that developed following the onset of COVID-19 symptoms. More detailed guidance is provided. Hospital admission: For patients who were admitted to hospital with COVID-19 or symptoms consistent with possible COVID-19 infection, please enter details for the date of hospital admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, original admission date should be provided, but all subsequent references to admission should be taken as referring to day COVID-19 was first clinically suspected (or within the first 24 hours after first day of suspected or confirmed COVID-19 infection). Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). Oxygen therapy: Include any form of supplemental oxygen received using any methods. Invasive ventilation: Please include any mechanical ventilation delivered following intubation or via a tracheostomy. Do not include patients who are breathing independently via a tracheostomy. Non-invasive ventilation: Please include any positive-pressure treatment given via a tight-fitted mask. This can be continuous positive pressure (CPAP) or bi-level positive pressure (BIPAP). Renal replacement therapy or dialysis: Please include any form of continuous renal replacement therapy or intermittent haemodialysis. Worst result: References to ‘worst result’ refer to those furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. pulse oximetry on poorly perfused extremities, haemolysed blood samples, contaminated microbiology results) should not be reported. The following measures should be considered as a single observation and entered together: Blood gas results: Please report the measures from the blood gas with the lowest pH (most acidotic). Blood pressure: Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Respiratory rate: If both abnormal low and high rate observed, record the abnormally high rate. General information about ISARIC ISARIC has developed a portfolio of resources to accelerate outbreak research and response. All resources are designed to address the most critical public health questions, have undergone extensive review by international clinical experts, and are free to use. ISARIC should be acknowledged and informed if you implement the protocol. Ethical apporval of the protocol and all necessary operational and financial arrangements are the responsibility of the investigators. This form refers to the CoV CASE RECORD FORM Version 1.3 25 Aug 2020. See https://isaric.tghn.org/COVID-19-CRF/

ISARIC/WHO Novel Coronavirus (nCoV) / COVID-19 Case Report Form - Module 2: Daily Case Report Form (CRF)

- 1/18/21 - 1 form, 5 itemgroups, 108 items, 1 language

Itemgroups: Administrative documentation, Signs and symptoms Part 1, Therapy, Signs and symptoms - Part 3, Laboratory Results

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies. Complete on the day of admission or first COVID-19 investigation, and on the first day of ICU admission (if different from day of admission). In addition, depending on available resources, complete every day for a maximum of 14 days, or for days when biochemical results are available. Module 1 and Module 2 complete on the first day of presentation/admission or on first day of COVID-19 assessment. Module 2 also complete on first day of admission to ICU or high dependency unit. In addition, complete daily for as many days as resources allow up to a maximum of 14 days. Continue to follow-up patients who transfer between wards. Module 3 (Outcome) complete at discharge or death General Guidance: - The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date. - For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline - Participant Identification Numbers consist of a 3 digit site code and a 4 digit participant number. You can obtain a site code and registering on the data management system by contacting ISARIC. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page. - Printed paper CRFs may be used for later transfer of the data onto the electronic database. - For participants who return for re-admission to the same site, start a new form with a different Participant Identification Number. Please check “YES-admitted previously” in the ONSET & ADMISSION section. Enter as 2 separate entries in the electronic database. - For participants who transfer between two sites that are both collecting data on this form, it is preferred to have the data entered by a single site as a single admission, under the same Participant Identification Number. When this is not possible, the first site should record “Transfer to other facility” as an OUTCOME, and the second site should start a new form with a new patient number and indicate “YES-transferred” in ONSET & ADMISSION. - Complete every line of every section, except for where the instructions say to skip a section based on certain responses. - Mark ‘Not done’ for any results of laboratory values that are not available, not applicable or unknown. - Avoid recording data outside of the dedicated areas. Sections are available for recording additional information. - If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS. - Place an (X) when you choose the corresponding answer. To make corrections, strike through (-------) the data you wish to delete and write the correct data above it. Please initial and date all corrections. - Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder. - ISARIC would like the centers to enter data directly into their electronic data capture system. Please contact ISARIC about access. If your site would like to collect data independently, ISARIC can support you in the estabilishment of locally hosted databases. This version may serve as a basis for locally hosted databases. - Please contact ISARIC, if you need help with databases, have comments or to let ISARIC know that you are using the CRF. - Please let us know if you find any mistakes in the MDM Portal's version. FURTHER GUIDANCE AND DEFINITIONS (from the Completion guideline) Comorbidities: Comorbidities present before the onset of COVID-19 and are still present. Do not include those that developed following the onset of COVID-19 symptoms. More detailed guidance is provided. Hospital admission: For patients who were admitted to hospital with COVID-19 or symptoms consistent with possible COVID-19 infection, please enter details for the date of hospital admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, original admission date should be provided, but all subsequent references to admission should be taken as referring to day COVID-19 was first clinically suspected (or within the first 24 hours after first day of suspected or confirmed COVID-19 infection). Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). Oxygen therapy: Include any form of supplemental oxygen received using any methods. Invasive ventilation: Please include any mechanical ventilation delivered following intubation or via a tracheostomy. Do not include patients who are breathing independently via a tracheostomy. Non-invasive ventilation: Please include any positive-pressure treatment given via a tight-fitted mask. This can be continuous positive pressure (CPAP) or bi-level positive pressure (BIPAP). Renal replacement therapy or dialysis: Please include any form of continuous renal replacement therapy or intermittent haemodialysis. Worst result: References to ‘worst result’ refer to those furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. pulse oximetry on poorly perfused extremities, haemolysed blood samples, contaminated microbiology results) should not be reported. The following measures should be considered as a single observation and entered together: Blood gas results: Please report the measures from the blood gas with the lowest pH (most acidotic). Blood pressure: Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Respiratory rate: If both abnormal low and high rate observed, record the abnormally high rate. General information about ISARIC ISARIC has developed a portfolio of resources to accelerate outbreak research and response. All resources are designed to address the most critical public health questions, have undergone extensive review by international clinical experts, and are free to use. ISARIC should be acknowledged and informed if you implement the protocol. Ethical apporval of the protocol and all necessary operational and financial arrangements are the responsibility of the investigators. This form refers to the CoV CASE RECORD FORM Version 1.3 25 Aug 2020. See https://isaric.tghn.org/COVID-19-CRF/

ISARIC/WHO Novel Coronavirus (nCoV) / COVID-19 Case Report Form - MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

- 1/18/21 - 1 form, 10 itemgroups, 112 items, 1 language

Itemgroups: Participant Identification, Clinical Inclusion Criteria, Demographics, Post Partum, Infant, Onset and admission, Signs and symptoms at hospital admission, Admission signs and symptoms, Pre-admission medication, Co-morbidities and risk factors

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies. Module 1 and Module 2 complete on the first day of presentation/admission or on first day of COVID-19 assessment. Module 2 also complete on first day of admission to ICU or high dependency unit. In addition, complete daily for as many days as resources allow up to a maximum of 14 days. Continue to follow-up patients who transfer between wards. Module 3 (Outcome) complete at discharge or death GENERAL GUIDANCE - The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date. - For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline - Participant Identification Numbers consist of a 3 digit site code and a 4 digit participant number. You can obtain a site code and registering on the data management system by contacting ISARIC. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page. - Printed paper CRFs may be used for later transfer of the data onto the electronic database. - For participants who return for re-admission to the same site, start a new form with a different Participant Identification Number. Please check “YES-admitted previously” in the ONSET & ADMISSION section. Enter as 2 separate entries in the electronic database. - For participants who transfer between two sites that are both collecting data on this form, it is preferred to have the data entered by a single site as a single admission, under the same Participant Identification Number. When this is not possible, the first site should record “Transfer to other facility” as an OUTCOME, and the second site should start a new form with a new patient number and indicate “YES-transferred” in ONSET & ADMISSION. - Complete every line of every section, except for where the instructions say to skip a section based on certain responses. - Mark ‘Not done’ for any results of laboratory values that are not available, not applicable or unknown. - Avoid recording data outside of the dedicated areas. Sections are available for recording additional information. - If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS. Place an (X) when you choose the corresponding answer. To make corrections, strike through (-------) the data you wish to delete and write the correct data above it. Please initial and date all corrections. Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder. - ISARIC would like the centers to enter data directly into their electronic data capture system. Please contact ISARIC about access. If your site would like to collect data independently, ISARIC can support you in the estabilishment of locally hosted databases. This version may serve as a basis for locally hosted databases. - Please contact ISARIC, if you need help with databases, have comments or to let ISARIC know that you are using the CRF. - Please let us know if you find any mistakes in the MDM Portal's version. FURTHER GUIDANCE AND DEFINITIONS (from the Completion guideline) Comorbidities: Comorbidities present before the onset of COVID-19 and are still present. Do not include those that developed following the onset of COVID-19 symptoms. More detailed guidance is provided. Hospital admission: For patients who were admitted to hospital with COVID-19 or symptoms consistent with possible COVID-19 infection, please enter details for the date of hospital admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, original admission date should be provided, but all subsequent references to admission should be taken as referring to day COVID-19 was first clinically suspected (or within the first 24 hours after first day of suspected or confirmed COVID-19 infection). Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). Oxygen therapy: Include any form of supplemental oxygen received using any methods. Invasive ventilation: Please include any mechanical ventilation delivered following intubation or via a tracheostomy. Do not include patients who are breathing independently via a tracheostomy. Non-invasive ventilation: Please include any positive-pressure treatment given via a tight-fitted mask. This can be continuous positive pressure (CPAP) or bi-level positive pressure (BIPAP). Renal replacement therapy or dialysis: Please include any form of continuous renal replacement therapy or intermittent haemodialysis. Worst result: References to ‘worst result’ refer to those furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. pulse oximetry on poorly perfused extremities, haemolysed blood samples, contaminated microbiology results) should not be reported. The following measures should be considered as a single observation and entered together: Blood gas results: Please report the measures from the blood gas with the lowest pH (most acidotic). Blood pressure: Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Respiratory rate: If both abnormal low and high rate observed, record the abnormally high rate. General information about ISARIC ISARIC has developed a portfolio of resources to accelerate outbreak research and response. All resources are designed to address the most critical public health questions, have undergone extensive review by international clinical experts, and are free to use. ISARIC should be acknowledged and informed if you implement the protocol. Ethical apporval of the protocol and all necessary operational and financial arrangements are the responsibility of the investigators. This form refers to the CoV CASE RECORD FORM Version 1.3 25 Aug 2020. See https://isaric.tghn.org/COVID-19-CRF/

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Cardio MRI

- 12/22/20 - 1 form, 23 itemgroups, 94 items, 1 language

Itemgroups: Clinical phase of CMR diagnostic, Indication for the cardiac MRI (CMR), Field strength, Manufacturer of CMR, Postprocessing software, Patient's cardiac device, Hematocrit, CMR procedure completed, Cardiac stress testing, Contrast Agent, Delayed contrast enhancement, CMR measurements, Mapping sequence, Mapping results, Edema on T2-weighted imaging, Wall motion abnormalities, Perfusion deficit during stress testing, Pericardium, Strain, Heart Rhythm, Assessment of the CMR, Additional information, Section completed

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 16:54 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. If a text field can't be filled out, note 'ND' (for not determined). The document will only be unlocked by LEOSS when requested and should be filled out by/together with a CMR-specialist.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Baseline II (General virological and laboratory findings for all phases)

- 12/4/20 - 1 form, 46 itemgroups, 320 items, 1 language

Itemgroups: Baseline: Types of virological testing, Baseline: PCR: Site of first detected SARS-CoV-2, Baseline: PCR: Tested target at first positive SARS-CoV-2 testing, Baseline: If pharyngeal swabs performed at SARS-CoV-2 testing: number of PCR cycles, Baseline: Anti-SARS-CoV-2 antibodies (IgG) titer measurement, Baseline: Anti-SARS-CoV-2 antibodies (IgA) titer measurement, Baseline: Laboratory values, Baseline: Hematological Values, Baseline: Other laboratory results, Baseline: Urine test strips, Uncomplicated phase: Types of virological testing, Uncomplicated phase: PCR: Sites of virological testing, Uncomplicated phase: If pharyngeal swabs performed at SARS-CoV-2 testing: number of PCR cycles, Uncomplicated phase: Viral coinfections, Uncomplicated phase: Anti-SARS-CoV-2 antibodies (IgG) titer measurement, Uncomplicated phase: Anti-SARS-CoV-2 antibodies (IgA) titer measurement, Uncomplicated phase: Laboratory values, Uncomplicated phase: Hematological Values, Uncomplicated phase: Other laboratory results, Complicated phase: Types of virological testing, Complicated phase: PCR: Sites of virological testing, Complicated phase: If pharyngeal swabs performed at SARS-CoV-2 testing: number of PCR cycles, Complicated phase: Viral coinfections, Complicated phase: Anti-SARS-CoV-2 antibodies (IgG) titer measurement, Complicated phase: Anti-SARS-CoV-2 antibodies (IgA) titer measurement, Complicated phase: Laboratory values, Complicated phase: Hematological Values, Complicated phase: Other laboratory results, Critical phase: Types of virological testing, Critical phase: PCR: Sites of virological testing, Critical phase: If pharyngeal swabs performed at SARS-CoV-2 testing: number of PCR cycles, Critical phase: Viral coinfections, Critical phase: Anti-SARS-CoV-2 antibodies (IgG) titer measurement, Critical phase: Anti-SARS-CoV-2 antibodies (IgA) titer measurement, Critical phase: Laboratory values, Critical phase: Hematological Values, Critical phase: Other laboratory results, Recovery phase: Types of virological testing, Recovery phase: PCR: Sites of virological testing, Recovery phase: If pharyngeal swabs performed at SARS-CoV-2 testing: number of PCR cycles, Recovery phase: Anti-SARS-CoV-2 antibodies (IgG) titer measurement, Recovery phase: Anti-SARS-CoV-2 antibodies (IgA) titer measurement, Recovery phase: Laboratory values, Recovery phase: Hematological Values, Recovery phase: Other laboratory results, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 16:54 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for baseline information and it contains the general virological and laboratory findings for all phases. It is closely related to Baseline I where further information is collected. Please keep in mind that the clinical phases represent time intervals while the baseline is a point in time. Data input of baseline and the clinical phase at diagnosis can but do not have to be identical. If a text field can't be filled out, note 'ND' (for not determined)

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Ethics and palliative care - related baseline data

- 12/4/20 - 1 form, 8 itemgroups, 41 items, 1 language

Itemgroups: Reasons for change of therapeutic goals from life-prolonging to palliative, Ethics consultation, Patient refusal of life-prolonging measures in case of life threatening disease, Specialist palliative care setting, Specialist palliative care type, Specialist palliative care professionals involved, Drugs prescribed for symptom control (breathlessness, pain, death rattle), Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 16:50 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Ethics and palliative care - related baseline data. If a text field can't be filled out, note 'ND' (for not determined).

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Emergency care - related baseline data

- 11/27/20 - 1 form, 12 itemgroups, 45 items, 1 language

Itemgroups: Patient arrival at emergency care unit, Results of lung ultrasound in emergency department to diagnose COVID-19, Initial therapeutic approaches performed in emergency department to treat COVID-19, Respiratory / airway management in emergency department, Oxygen inhalation, High flow nasal cannula (HFNC) - specify, Mechanical ventilation - specify ventilator settings, BIPAP settings of pressure, Mechanical ventilation mean positive endexpiratory pressure (PEEP), Mechanical ventilation mean fraction of inspired oxygen (FIO2), Information concerning admission / discharge after initial emergecy department visit, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 15:43 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Emergency care - related baseline data. If a text field can't be filled out, note 'ND' (for not determined). Notification: You are cordially to participate in the Registry for COVID-19 in the Emergency Room (ReCovER) for deeper characterization of diagnostic and therapeutical approaches for COVID-19 in emergency medicine. Please visit www.covid-em.org for further information.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Rheuma-related baseline data

- 11/27/20 - 1 form, 4 itemgroups, 44 items, 1 language

Itemgroups: Rheumatic disease, Disease duration, Organ manifestations, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 15:18 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Rheuma-related baseline data. All questions refer to the day of diagnosis (diagnosis means first positive virus result). Please note that only cases with known outcome are collected at LEOSS! If a text field can't be filled out, note 'ND' (for not determined)

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Oncology related data

- 11/27/20 - 1 form, 12 itemgroups, 54 items, 1 language

Itemgroups: Hypogammaglobuliaemia, specific: IgG, Underlying disease: Hematological, Underlying disease: Other solid tumors, Underlying disease: Other, Specification of NHL as underlying disease, Diagnosis date of hematological / oncological disease, ECOG (Eastern Co-operative Oncology Group) at baseline, Status at detection of SARS-CoV-2, Anti-cancer therapy, Checkpoint inhibitor therapy (last 3 months), Stem cell transplantation, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 15:10 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Oncology related data. All questions refer to the day of diagnosis (diagnosis means first positive virus result). Please note that only cases with known outcome are collected at LEOSS!

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Neurology - related baseline data

- 11/27/20 - 1 form, 16 itemgroups, 123 items, 1 language

Itemgroups: Specification of neurological comorbidities, Cerebrovascular disease, Medication of Cerebrovascular disease, MS subtype, MS: Immunomodulatory medication at first detection of SARS-CoV-2, MS: Immunomodulatory therapy was discontinued..., Relapse treatment for multiple sclerosis in the last three months, Severity of MS and B-cells at diagnosis of SARS-CoV-2, Neurological diagnostic: If neurological imaging (cCT, cMRI) was performed, please specify, Neurological diagnostic: If an EEG was performed, please specify, Neurological diagnostic: If electrophysiology was performed, please specify, Neurological diagnostic: If a spinal tap was performed, please specify, Cerebrospinal fluid: Pathogen and antibody testing status, Neurodegeneration, Neurological medication prior to current disease, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 14.10.2020, 16:02 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for Neurology - related baseline data. If a text field can't be filled out, note 'ND' (for not determined).

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - HIV-related baseline data

- 11/27/20 - 1 form, 13 itemgroups, 55 items, 1 language

Itemgroups: HIV transmission risk, Current antiretroviral therapy, Antiretroviral therapy duration before SARS-CoV-2 detection, Antiretroviral therapy changed / started during SARS-Cov-2 infection, Antiretroviral therapy regimen at end of follow-up period, CD4+ T-cell count (abs.), CD4+ T-cell count (rel.), HIV CDC stage at baseline, CD8+ T-cell count (abs.), CD8+ T-cell count (rel.), HIV viral load, Opportunistic infections, AIDS-defining illnesses, STI during COVID-19, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 14.10.2020, 15:07:14 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS is mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society. It aims at a better understanding of the implications of the new virus on patients by systematically documenting patient data across Europe (Text adapted from leoss.net). For more information please visit the official website. This document is for HIV-related baseline data. All questions refer to the day of diagnosis (diagnosis means first positive virus result). Please note that only cases with known outcome are collected at LEOSS! If a text field can't be filled out, note 'ND' (for not determined).

Keywords

Table of contents

Selected data models

29 Search results.